| |
Overall
| |
Survival
| |
Mortality
| |
Telbivudine
| |
Entecavir
| |
|---|
|
Patient no
|
21
| |
17
| |
4
| |
9
| |
12
| |
|---|
|
Time point
|
Baseline
|
Week 2
|
p
|
Baseline
|
Week 2a
|
p
|
Baseline
|
Week 2a
|
P
|
Baseline
|
Week 2b
|
p
|
Baseline
|
Week 2b
|
p
|
|---|
|
ALT
|
1270 (146–2480)
|
167 (41–485)
|
<0.001
|
1270 (211–2480)
|
184 (41–485)
|
<0.001
|
1197 (146–2247)
|
112.5 (66–190)
|
0.068
|
1523 (211–2480)
|
184 (80–435)
|
0.011
|
870 (146–2247)
|
133.5 (41–485)
|
0.002
|
|
Bilirubin T
|
9.2 (2.1–33.1)
|
6.8 (1.8–43.2)
|
0.728
|
7.7 (2.1–16.8)
|
4.8 (1.8–21.3)
|
0.309
|
20.6 (11.9–33.1)
|
29.1 (17.8–43.2)
|
0.068
|
8.6 (2.1–20.4)
|
8.0 (1.9–25.3)
|
0.515
|
10.25 (2.2–33.1)
|
5.15 (1.8–43.2)
|
1.000
|
|
Creatinine
|
0.68 (0.39–1.46)
|
0.94 (0.37–3.79)
|
0.002
|
0.71 (0.47–1.34)
|
1.0 (0.37–1.81)
|
0.019
|
0.48 (0.39–1.46)
|
0.92 (0.72–3.79)
|
0.068
|
0.71 (0.47–1.05)
|
0.90 (0.59–1.49)
|
0.051
|
0.63 (0.39–1.46)
|
1.03 (0.37–3.79)
|
0.021
|
|
eGFR
| | | | | | | | | | | | | | | |
|
MDRD
|
116 (53–254)
|
89 (18–241)
|
0.005
|
116 (53–183)
|
77 (37–241)
|
0.042
|
194.5 (54–254)
|
90.5 (18–129)
|
0.068
|
116 (73–201)
|
89 (37–147)
|
0.044
|
127 (53–254)
|
79 (18–241)
|
0.050
|
|
CKD-EPI
|
111.1 (52.9–156.7)
|
98.3 (18.9–134.5)
|
0.003
|
110.1 (52.9–131.1)
|
82.9 (36.8–134.5)
|
0.028
|
138.2 (59.8–156.7)
|
101.8 (18.9–126.4)
|
0.068
|
112 (77.8–148)
|
98.3 (40.9–126.4)
|
0.066
|
110.6 (5.29–56.7)
|
86.9 (18.9–134.5)
|
0.028
|
|
INR
|
1.6 (1.3–3.5)
|
1.4 (1.0–4.2)
|
0.066
|
1.5 (1.3–2.3)
|
1.3 (1.0–2.8)
|
0.062
|
3.3 (2.6–3.5)
|
2.75 (2.2–4.2)
|
0.577
|
1.5 (1.3–3.1)
|
1.7 (1.1–2.8)
|
0.440
|
1.6 (1.4–3.5)
|
1.35 (1.0–4.2)
|
0.058
|
|
AFP
|
65.7 (4.1–650.7)
|
305.5 (6.2–2802)
|
0.013
|
49.4 (4.1–477.2)
|
459.6 (35.4–2802)
|
0.005
|
109.5 (27.9–650.7)
|
36.3 (6.2–66.3)
|
0.180
|
27.9 (4.2–238.3)
|
191.9 (66.3–1462.5)
|
0.046
|
162.1 (4.1–650.7)
|
459.6 (6.2–2802)
|
0.139
|
|
HBV DNA (log10 cps/ml)
|
8.04 (4.3–9.68)
|
4.19 (3.07–5.89)
|
<0.001
|
8.16 (5.22–5.06)
|
4.2 (3.07–5.89)
|
0.001
|
5.06 (4.3–8.2)
|
3.64 (3.31–3.96)
|
0.180
|
8.04 (4.97–9.47)
|
3.96 (3.07–5.10)
|
0.018
|
8.04 (4.30–9.68)
|
4.20 (3.13–5.89)
|
0.005
|
|
MELD score
|
20 (13–37)
|
19 (11–49)
|
0.283
|
19 (13–28)
|
17 (11–32)
|
0.166
|
31.5 (26–.7)
|
30 (26–49)
|
0.655
|
19 (14–31)
|
20 (11–32)
|
0.674
|
20 (13–37)
|
18 (11–49)
|
0.469
|
- Data shown as median (range); eGFR estimated glomerular filtration rate, MDRD modification of diet in renal disease (mL/min/1.73m2), CKD-EPI Chronic Kidney Disease Epidemiology Collaboration (mL/min/1.73m2), INR international normalized ratio, AFP alpha-fetoprotein, MELD model for end-stage liver disease.
- a: comparison of week 2 data between survival and mortality, p values in order were 0.324, 0.003, 0.720, 0.788, 1.000, 0.004, 0.039, 0.160, 0.006.
- b: comparison of week 2 data between Telbivudine and Entecavir, p values in order were 0.394, 0.776, 0.776, 0.803, 0.670, 0.642, 1.000, 0.242, 0.915.
